Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy

Authors

Leslie Robin Halpern, New York Medical College/NYCHHC, Metropolitan Hospital, 100 Woods Road, Valhalla, NY 10593, USA. Electronic address: halpernl@nychhc.org.
David Russell Adams, Section head, Oral and Maxillofacial Surgery, University of Utah, School of Dentistry, 530 South Wakara Way, Salt Lake City, UT 84108, USA.

Author Type(s)

Faculty

DOI

10.1016/j.cden.2023.07.005

Journal Title

Dental Clinics of North America

First Page

67

Last Page

85

Document Type

Article

Publication Date

1-1-2024

Department

Dental Medicine

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a most interesting, complex and "elusive" condition seen by the oral health care provider. It is plagued by controversy and although a wealth of research has created clinical treatment databases, there is no "gold standard" algorithm to be applied in a universal fashion. The purpose of this article is to explore several controversies associated with the etiology(s), staging, treatments, and long-term resolution of MRONJ in patients who are treated by the oral health care provider. Controversies for optimizing prevention, and disease control will also be discussed from an interdisciplinary perspective.

Recommended Citation

Halpern, L. R., & Adams, D. R. (2024). Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy. Dental Clinics of North America, 68 (1), 67-85. https://doi.org/10.1016/j.cden.2023.07.005